The Application of GHRH Antagonist as a Treatment for Resistant APL

Area of Science:

• Oncology
• Endocrinology
• Molecular Biology

Background:

• Growth hormone-releasing hormone (GHRH) stimulates malignant cell proliferation.
• GHRH antagonists, like MIA-602, have previously shown efficacy in suppressing diverse human cancer cell lines.
• The presence and role of GHRH receptors (GHRH-R) in specific leukemia models require further elucidation.

Purpose of the Study:

• To investigate the presence of GHRH-R in NB4, NB4-RAA, and K-562 leukemia cell lines.
• To evaluate the efficacy of the GHRH antagonist MIA-602 in inhibiting the proliferation of these cell lines in vitro and in vivo.
• To assess the synergistic effects of MIA-602 in combination with standard chemotherapies for acute myeloid leukemia (AML).

Main Methods:

• Detection of GHRH-R expression in NB4, NB4-RAA, and K-562 cell lines.
• In vitro proliferation assays of leukemia cell lines treated with MIA-602.
• In vivo studies using xenografts of human APL cell lines treated with MIA-602.
• Combination therapy experiments involving MIA-602 and doxorubicin (DOX) in K-562 AML cells.

Main Results:

• GHRH-R expression was confirmed in NB4, NB4-RAA, and K-562 cell lines.
• MIA-602 significantly inhibited the proliferation of all three tested leukemia cell lines in vitro.
• Treatment with MIA-602 led to a substantial reduction in tumor growth in human APL xenograft models.
• Combination therapy of MIA-602 and doxorubicin demonstrated a synergistic effect in reducing K-562 AML cell proliferation.

Conclusions:

• MIA-602 effectively inhibits GHRH-R expressing leukemia cell lines.
• MIA-602 demonstrates therapeutic potential as a single agent and in combination therapies for AML.
• MIA-602 may overcome resistance to standard therapies like all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), and augment anthracycline-based regimens.